Sergio Traversa, Chief Executive Officer at RELMADA THERAPEUTICS, INC. (RLMD), bought 30 shares at $2.97 ($89) on 2015-12-14, disclosed to the SEC on 2015-12-16.
Open-market purchase of $89 RLMD by Chief Executive Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| Filing → |
| RLMD | BUY | 2025-11-06 | $600K | — | Filing → |
| RLMD | BUY | 2025-08-28 | $265K | — | Filing → |
| RLMD | BUY | 2025-05-20 | $335K | — | Filing → |